EquityBulls

Latest News

Keywords Selected: INE326A01037

Research

Lupin - Q1FY23 Result Update - Margin disappointment continues - HOLD

Stock Report

Lupin Receives EIR from U.S. FDA for its Nagpur Unit-1 Manufacturing Facility
Lupin's Joint Airways Initiative surpasses 10,000 Patients
Lupin acquires Five Brands from Menarini
Lupin Collaborates with Mark Cuban Cost Plus Drug Company and COPD Foundation to Expand Access to Medication for COPD Patients
Lupin Launches Propranolol Long-Acting Capsules to Improve Heart Health in Canada
Lupin Receives Approval from U.S. FDA for Pirfenidone Capsules
Lupin receives approval from U.S. FDA for Pirfenidone Tablets
Lupin acquires brands ONDERO® and ONDERO MET® to expand Diabetes Portfolio in India
Lupin Launches Tiotropium Dry Powder for Inhaler for the Treatment of COPD in the United States
Lupin launches Jeet, a Patient Support Program to raise awareness of Cardiovascular Disease among Patients
Lupin receives approval from U.S. FDA for Metoprolol Succinate Extended-Release Tablets USP
Lupin receives approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.09%
Lupin receives approval from U.S. FDA for Doxycycline Hyclate Delayed-Release Tablets USP
Lupin's Mandideep Unit-2 Facility Completes U.S. FDA Inspection with No Observations
Lupin receives approval from U.S. FDA for Fluocinolone Acetonide Body Oil
Lupin receives approval from U.S. FDA for Fluocinolone Acetonide Topical Oil
Lupin receives approval from US FDA for Turqoz®
Lupin receives approval from TGA Australia for Tiotropium Dry Powder for Inhaler for Treatment of COPD
Lupin receives tentative approval from U.S. FDA for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets
Lupin Launches Luforbec® 100/6 for Adult Asthma and COPD Treatment in Germany
Lupin receives approval from U.S. FDA for Chlorpromazine Hydrochloride Tablets USP
Lupin's Nagpur Oral Solid Dosage facility gets 2 observations from USFDA
Lupin receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility
Lupin receives Tentative Approval from U.S. FDA for Dolutegravir Tablets for Oral Suspension